Engaging diverse communities participating in clinical trials: Case examples from across Africa

Malaria Journal

Volumn 9, Issue 1, 2010, Pages

  Nyika, Aceme ^a   Chilengi, Roma ^b   Ishengoma, Deus ^c   Mtenga, Sally ^d   Thera, Mahamadou A ^e   Sissoko, Mahamadou S ^e   Lusingu, John ^c   Tiono, Alfred B ^f   Doumbo, Ogobara ^e   Sirima, Sodiomon B ^f   Lemnge, Martha ^c   Kilama, Wen L ^a  

^a African Malaria Network Trust AMANET   (Tanzania)

^b KEMRI WELLCOME TRUST RESEARCH PROGRAMME   (Kenya)

^c NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (Tanzania)

^d IFAKARA HEALTH INSTITUTE   (Tanzania)

^e UNIVERSITY OF BAMAKO   (Mali)

^f Burkina Faso   (Burkina Faso)

Author keywords

[No Author keywords available]

Indexed keywords

APICAL MEMBRANE ANTIGEN 1; GLUTAMATE RICH PROTEIN; MALARIA VACCINE; MEROZOITE SURFACE PROTEIN 3; MEROZOITE SURFACE PROTEIN 3 IN THE LONG SYNTHETIC PEPTIDE CONFIGURATION; PARASITE ANTIGEN; PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BURKINA FASO; COMMUNITY PROGRAM; GABON; HEALTH CARE ORGANIZATION; HUMAN; INFORMED CONSENT; MALARIA; MALI; MEDICAL RESEARCH; PRACTICE GUIDELINE; SAMPLING; TANZANIA; AFRICA; CLINICAL TRIAL; HEALTH CARE DELIVERY; IMMUNOLOGY; INTERNATIONAL COOPERATION; MALARIA FALCIPARUM; METHODOLOGY; ORGANIZATION AND MANAGEMENT; PARASITOLOGY; PARTICIPATORY RESEARCH; PLASMODIUM FALCIPARUM;

AFRICA; BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; COMMUNITY-BASED PARTICIPATORY RESEARCH; DELIVERY OF HEALTH CARE; HUMANS; INTERNATIONAL COOPERATION; MALARIA VACCINES; MALARIA, FALCIPARUM; PLASMODIUM FALCIPARUM; RESEARCH DESIGN;

EID: 77951108279     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-9-86     Document Type: Article

References (34)

1. It takes a village: medical research and ethics in Mali. O Doumbo, Science 2005 307 679 681 10.1126/science.1109773 15692036
2. Community permission for medical research in developing countries. DA Diallo OK Doumbo CV Plowe TE Wellems EJ Emanuel SA Hurst, Clin Infect Dis 2005 41 255 259 10.1086/430707 15983925
3. Valid consent for genomic epidemiology in developing countries. DA Chokshi MA Thera M Parker M Diakite J Makani DP Kwiatkowski OK Doumbo, PLoS Med 2007 4 95 10.1371/journal.pmed.0040095 17455985
4. Grand challenges in global health: community engagement in research in developing countries. PO Tindana JA Singh CS Tracy REG Upshur AS Daar PA Singer J Frohlich JV Lavery, Plos Med 2007 4 273 10.1371/journal.pmed.0040273 17850178
5. Popular concerns about medical research projects in sub-Saharan Africa: a critical voice in debates about medical ethics. PW Geissler R Pool, Trop Med Int Health 2006 11 975 982 10.1111/j.1365-3156.2006.01682.x 16827698
6. Designing research in vulnerable populations: lessons from HIV prevention trials that stopped early. EJ Mills S Singh JA Singh JJ Orbinski M Warren RE Upshur, BMJ 2005 331 1403 1406 10.1136/bmj.331.7529.1403 16339256
7. Breast cancer, the genetic "quick fix", and the Jewish community. Ethical, legal and social challenges. KH Rothenberg, Health Matrix 1997 7 97 124 10167180
8. The APCI1307K allel and cancer in a community-based study of Ashkenazi Jews. T Woodage SM King S Wacholder P Hartge JP Struewing M McAdams SJ Laken MA Tucker LC Brody, Nat Genet 1998 20 62 65 10.1038/1722 9731533
9. Toward a framework of mutualism: the Jewish community in genetics research. K Rothenberg AB Rutkin, Commun Genet 1998 1 148 153 10.1159/000016154
10. The International HapMap Project. International HapMap Consortium, Nature 2003 426 789 796 10.1038/nature02168 14685227
11. Integrating ethics and science in the International HapMap Project. http://www.nature.com/nrg/journal/v5/n6/full/nrg1351.html
12. Council for International Organizations of Medical Sciences (CIOMS): International Ethical Guidelines for Biomedical Research Involving Human Subjects. http://www.cioms.ch/guidelines-nov-2002-blurb.htm
13. Council for International Organizations of Medical Sciences (CIOMS): International ethical guidelines for epidemiological studies. http://www.cioms.ch/frame-ethical-guidelines-2009.htm
14. The ethics of research related to healthcare in developing countries. 2002 Report. Nuffield Council on Bioethics, http://www.nuffieldbioethics.org/ fileLibrary/pdf/errhdc-fullreport001.pdf
15. What makes clinical research ethical? EJ Emanuel D Wendler C Grady, JAMA 2000 283 2701 2711 10.1001/jama.283.20.2701 10819955
16. African Malaria Network Trust(AMANET). http://www.amanet-trust.org/
17. Safety and immunogenicity of the Plasmodium falciparum merozoite surface protein-3 long synthetic peptide (MSP3-LSP) malaria vaccine in healthy, semi-immune adult males in Burkina Faso, West Africa. SB Sirima I N'ebi'e A Ou'edraogo AB Tiono A Konat'e Gansan'e AI Derm'e A Diarra A Ou'edraogo I Soulama N Cuzzin-Ouattara S Cousens O Leroy, Vaccine 2007 25 2723 2732 10.1016/j.vaccine.2006.05.090 17280744
18. Safety and immunogenicity of the malaria vaccine candidate MSP3 Long Synthetic Peptide in 12-24 months-old Burkinabe children. SB Sirima AB Tiono A Ouédraogo A Diarra AL Ouédraogo JB Yaro E Ouédraogo A Gansané E Bougouma AT Konaté Y Kaboré A Traoré R Chilengi I Soulama AJF Luty S Cousens I Nébié Plos One 2009 4 7549 10.1371/journal.pone.0007549 19855847
19. Press Release: AMANET Launches Clinical Trial of Candidate Malaria Vaccine AMA1 in Mali. http://www.amanet-trust.org/ext/news/pressAMA1.htm
20. Towards an African-Driven Malaria Vaccine Development Program: History and Activities of the African Malaria Network Trust (AMANET). WL Kilama R Chilengi CL Wanga, Am J Trop Med Hyg 2007 77 282 288 18165504
21. AMANET Launches Large-Scale Testing of Candidate Malaria Vaccine MSP3-LSP in Mali. http://www.amanet-trust.org/ext/news/pressMSP3-LSP2.htm
22. The Malaria Research and Training Center. http://obtoure.africa-web.org/ MRTC.htm
23. Safety and Immunogenicity of 30 and 100 g of GMZ2 in Gabonese Children Aged 1-5 Years. http://clinicaltrials.gov/ct2/show/NCT00703066
24. National Institute of Medical Research Tanga Centre. http://www. nimrtanga.org/home.html
25. Epidemiology of malaria in an area prepared for clinical trials in Korogwe, north-eastern Tanzania. BP Mmbando MD Segeja HA Msangeni SH Sembuche DS Ishengoma MD Seth F Francis AS Rutta ML Kamugisha MM Lemnge, Malar J 2009 8 165 10.1186/1475-2875-8-165 19615093
26. Satisfactory safety and immunogenicity of MSP3 malaria vaccine candidate in Tanzanian children aged 12-24 months. JPA Lusingu S Gesase S Msham F Francis MM Lemnge M Seth S Sembuche A Rutta D Minja MD Segeja S Bosomprah S Cousens R Noor R Chilengi P Druilhe, Malar J 2009 8 163 10.1186/1475-2875-8-163 19607731
27. Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. P Bejon J Lusingu A Olotu A Leach M Lievens J Vekemans S Mshamu T Lang J Gould M Dubois M Demoitié J Stallaert P Vansadia T Carter P Njuguna KO Awuondo A Malabeja O Abdul S Gesase N Mturi CJ Drakeley B Savarese T Villafana WR Ballou J Cohen EM Riley MM Lemnge K Marsh L Seidlein, NEJM 2008 359 2521 2532 10.1056/NEJMoa0807381 19064627
28. Ifakara Health Institute (IHI). http://www.ihi.or.tz/
29. New Malaria Clinical Trial Site Inaugurated at Bagamoyo, Tanzania. http://www.mmv.org/article.php3?id-article=362
30. RBx11160 Phase II Dose Ranging Study RBx/MMV05-06. http://clinicaltrials. gov/ct2/show/NCT00362050
31. Phase 3 malaria vaccine trial begins - final testing of RTS,S. http://www.malariavaccine.org/RTSSPhase3-05-27-2009.php
32. Safety and Immunogenicity of RTS,S/AS02D Malaria Vaccine in Infants. S Abdulla R Oberholzer O Juma S Kubhoja F Machera C Membi S Omari A Urassa H Mshinda A Jumanne N Salim M Shomari T Aebi DM Schellenberg T Carter T Villafana M Demoitié M Dubois A Leach M Lievens J Vekemans J Cohen WR Ballou M Tanner, NEJM 2008 359 2533 2544 10.1056/NEJMoa0807773 19064623
33. Community based trials and informed consent in rural North India. A DeCosta N D'Souza S Krisnan MS Chabra I Shihaam K Goswami, JME 2004 30 318 323
34. The effect of relationships on decision-making process of women in Harare, Zimbabwe. A Nyika DR Wassenaar N Mamotte, Ethics & Behavior 2009 19 184 200